human clinical trials – MJ Shareholders https://mjshareholders.com The Ultimate Marijuana Business Directory Mon, 30 Aug 2021 11:45:43 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.5 Big Data and AI Can Guide Cannabis Medicine https://mjshareholders.com/big-data-and-ai-can-guide-cannabis-medicine/ Mon, 30 Aug 2021 11:45:43 +0000 https://www.cannabisfn.com/?p=2932074

Robin Lefferts

August 30th, 2021

App, Exclusive, News, Top Story


In order for cannabis medicine to make the big leap to mainstream acceptance, a few things likely have to take place. Doctors, not just cannabis providers, need to become more comfortable discussing and prescribing the plant. Regulations need to become more homogenous and universal, like the pharmaceutical industry. Pharma companies need to advance more cannabis-derived medicines for approval.

In order for those things to happen, robust data around the efficacy of cannabis treatments needs to be gathered and widely understood. In the meantime, cannabis patients and providers are often stuck with a personal trial-and-error approach to finding the right treatment for their own needs. RYAH Group Inc. (CSE: RYAH) is one company that is pushing forward in all of these areas. The company’s smart delivery devices, database with over 200,000 users, and artificial intelligence-powered data engine combine to form a powerful Internet of Things solution with the potential to more fully legitimize cannabis medicine while making it more effective for current patients.

Moving the Industry Forward

Regulators like the United States Food and Drug Administration (FDA) need data to make informed decisions. Big pharma companies need data to even undertake research programs aimed at developing new potential drugs. Doctors need data to feel comfortable giving prescriptions or recommendations for treatment.

Since the cannabis industry is so young, was prohibited for so long, and still faces a myriad of patchwork and inconsistent regulations, cannabis medicine is severely lacking the large datasets that are crucial for the industry’s development. In this regard, RYAH is well-positioned to provide all interested parties with the information necessary for growth and advancement.

RYAH’s Data Sharing Benefits

The company’s smart devices and data solutions are gaining traction with cannabis researchers across the globe. The controlled dosing, easily recorded personal feedback from patients, wealth of data stored in RYAH’s Cloud database, and AI-powered data interpretation and organization give researchers tools that make their studies more effective and efficient. RYAH is involved in trials and studies in Britain, Italy, Italy again, and the Channel Islands. The company also has deals in France and New Zealand for distribution and potential inclusion in clinical trials and major studies.

RYAH’s goal is to provide regulators, researchers, and drug companies all the data they need to mainstream plant-based medicine, and it looks like the company is on its way.

Click here to receive an investor presentation and corporate updates

Improving the Patient Experience

RYAH’s smart devices, connected apps, and AI data interpreter can help patients and doctors effectively hone a treatment regimen according to the patient’s own feedback combined with that of the other users in the system. Without the insights from a large patient pool and the ability to easily record, track, and interpret personal experiences and preferences, many cannabis patients can get a little lost. Which strain? What is the proper dose? Has this particular type of treatment worked for other people?

Watch how Ryah technology Benefits to Patients and Doctors

RYAH’s system offers control and assurance, not only to researchers and patients involved in clinical trial programs but also to normal, everyday medical cannabis users in search of a little guidance. To many, using cannabis presents a great unknown fraught with risks. RYAH helps to alleviate those concerns and bring the cannabis patient experience more in line with that of conventional patients.

The Takeaway

This type of system is right in line with the larger trend toward tele-health and the use of machine learning and artificial intelligence to improve patient outcomes. Overall, the market for remote treatment is growing at a 26.5% CAGR, expected to reach $475 billion in the next five years. It’s a huge trend in healthcare, and RYAH is at the forefront of the movement in the cannabis industry.

The two aspects of RYAH’s business go hand in hand, improving treatments for cannabis patients while providing data and a platform that enables research and regulation that will further legitimize the industry as a whole. Keep an eye out for continued developments in the RYAH story.

Click here to receive an investor presentation and corporate updates

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Robin Lefferts

Robin Lefferts has been involved in the legal cannabis industry since 2012, sometimes as an active participant and always as an interested observer.


]]>
Cardiol Therarpeutics Receives FDA Approval For Investigational New Drug (IND) Application For Phase II/III COVID-19 Trial https://mjshareholders.com/cardiol-therarpeutics-receives-fda-approval-for-investigational-new-drug-ind-application-for-phase-ii-iii-covid-19-trial/ Fri, 25 Sep 2020 13:03:44 +0000 https://www.cannabisfn.com/?p=2818943

Ryan Allway

September 25th, 2020

News, Top News


Trial will take place at major U.S. centers and examine the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease (CVD)

Oakville, Ontario–(Newsfile Corp. – September 25, 2020) – Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (“Cardiol” or the “Company“), a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory heart disease, is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application to commence a Phase II/III, double-blind, placebo-controlled clinical trial investigating the efficacy and safety of CardiolRx™, a pharmaceutically produced extra strength cannabidiol formulation, in 422 hospitalized COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease (CVD). The trial will take place at major centers in the United States, where the prevalence of COVID-19 remains high.

Patients with COVID-19 primarily present with respiratory symptoms which can progress to bilateral pneumonia and serious pulmonary complications. It is now recognized that the impact of COVID-19 is not limited to the pulmonary system. Individuals with pre-existing CVD or who have risk factors for CVD (such as diabetes, hypertension, obesity, abnormal serum lipids, or age greater than 64) are at significantly greater risk of developing serious disease from COVID-19 and experience greater morbidity. Moreover, such COVID-19 patients are at significant risk of developing cardiovascular complications (such as acute myocardial infarction, cardiac arrhythmias, myocarditis, stroke, and heart failure) during the course of their illness, and which are frequently fatal, with an estimated 30 – 40% of patients who die from COVID-19 doing so from cardiovascular complications. A strategy to prevent or limit the number or severity of these cardiovascular complications is likely to considerably improve outcomes from this disease.

Cardiol’s Phase II/III trial has been designed to assess the efficacy, safety, and tolerability of CardiolRx™ in preventing cardiovascular complications in hospitalized patients, with a confirmed diagnosis of COVID-19 within the previous 24 hours, and who have pre-existing CVD and/or significant risk factors for CVD. The composite primary efficacy endpoint will be the difference between the active and placebo groups in the percentage of patients who develop, during the first twenty-eight days following randomization and first dose of study medication, a composite endpoint consisting of one or more of several common outcomes in this patient population, including all-cause mortality, requirement for ICU admission and/or ventilatory support, as well as cardiovascular complications, including the development of heart failure, acute myocardial infarction, myocarditis, stroke, or new sustained or symptomatic arrhythmia.

The study was designed and will be overseen by an independent Steering Committee, consisting of international thought leaders in inflammatory heart disease: Dr. Dennis McNamara (Chair), Professor of Medicine and Director of the Center for Heart Failure Research, University of Pittsburgh; Dr. Leslie Cooper (Co-Chair), Chair of the Mayo Clinic Enterprise Department of Cardiovascular Medicine and Chair of the Department of Cardiovascular Medicine, Mayo Clinic; Dr. Arvind Bhimaraj, Medical Director, Advanced Heart Failure, Mechanical Circulatory Support and Heart Transplant Programs, Houston Methodist Hospital; Dr. Barry Trachtenberg, Director, Cardio-Oncology and Cardiac Amyloid Programs, Associate Director, Mechanical Circulatory Support Program, Houston Methodist Hospital; Dr. Wilson Tang, Director of the Center for Clinical Genomics, Research Director, and staff cardiologist in the Section of Heart Failure and Cardiac Transplantation Medicine, Cleveland Clinic; Dr. Peter Liu, Chief Scientific Officer and Vice President of Research, University of Ottawa Heart Institute; Dr. Carsten Tschöpe, Vice Director of the Dept. of Cardiology, Charité University Medicine Berlin, Germany; and Dr. Matthias Friedrich, Professor of Medicine and Chief, Cardiovascular Imaging, McGill University Health Centre.

Dr. Dennis McNamara, Chair of the Steering Committee for the trial commented: “As a Steering Committee, we are excited about the potential for this study to contribute valuable new information about the role of anti-inflammatory agents in the management of COVID-19. Now that approval from the FDA has been granted, we are anxious to get underway so that we can investigate the impact of CardiolRx in this very important disease process.”

“Receiving approval from the FDA for our IND application to initiate a clinical program in COVID-19 patients represents a major milestone for Cardiol Therapeutics and provides the opportunity to significantly accelerate the commercial development of CardiolRx,” said David Elsley, President and CEO of Cardiol Therapeutics. “The COVID-19 pandemic is providing our Company with a unique opportunity to rapidly study the cardioprotective properties of CardiolRx in patients who have a prior history of, or risk factors for, cardiovascular disease and are most vulnerable to the virus. Subject to study outcomes, our discussions with the FDA indicated that the design and scope of our Phase II/III trial may be used as a registration study in support of a New Drug Application.”

The rationale for using cannabidiol to treat patients with COVID-19 is based on extensive pre-clinical investigations by Cardiol and others in models of cardiovascular inflammation which have demonstrated that CBD has impressive anti-inflammatory and anti-fibrotic activity, as well as anti-ischemic, and anti-arrhythmic action, and that it improves myocardial function in models of heart failure. In pre-clinical models of cardiac injury, cannabidiol was shown to be cardio-protective by reducing cardiac hypertrophy, fibrosis, and the production of certain re-modelling markers, such as cardiac B-type Natriuretic Peptide (BNP), which is typically elevated in patients with heart failure. These data were accepted for presentation at the American College of Cardiology’s 69th Annual Scientific Session held virtually on March 28 – 30, 2020.

About Cardiol Therapeutics

Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) is a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory heart disease. The Company recently received approval from the U.S. FDA for its Investigational New Drug (IND) application to commence a Phase II/III, double-blind, placebo-controlled clinical trial investigating the efficacy and safety of its lead product, CardiolRx™, in hospitalized COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease (CVD). CardiolRx™ is an ultra-pure, high concentration cannabidiol oral formulation that is pharmaceutically produced, manufactured under cGMP, and THC free (<5 ppm).

Cardiol is also planning a Phase II international trial of CardiolRx™ in acute myocarditis, a condition caused by inflammation in heart tissue, which remains the most common cause of sudden cardiac death in people less than 35 years of age, and developing proprietary cannabidiol formulations for the treatment of chronic heart failure. Chronic heart failure is the leading cause of death and hospitalization in North America, with associated annual healthcare costs in the U.S. alone exceeding $30 billion. For further information about Cardiol Therapeutics, please visit cardiolrx.com.

For further information, please contact:

David Elsley, President & CEO +1-289-910-0850
[email protected]

Trevor Burns, Investor Relations +1-289-910-0855
[email protected]

Cautionary statement regarding forward-looking information:

This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol Therapeutics Inc. (“Cardiol” or the “Company”) believes, expects, or anticipates will, may, could or might occur in the future are “forward- looking information”. Forward-looking information contained herein may include, but is not limited to, statements with respect to that, subject to study outcomes, our Phase II/III study may be used as a registration study in support of a New Drug Application, the opportunity to significantly accelerate the commercial development of CardiolRx, the Company’s plans for a Phase II international trial of CardiolRx™ in acute myocarditis, its development of a proprietary cannabidiol formulation for the treatment of chronic heart failure, the potential for this study to contribute valuable new information about the role of anti-inflammatory agents in the management of COVID-19, and the likely improvement of outcomes from COVID-19 resulting from a strategy to prevent or limit the number or severity of cardiovascular complications. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company’s Annual Information Form dated March 30, 2020, including the risks and uncertainties associated with product commercialization and clinical studies, and uncertainties in predicting treatment outcomes. These risks, uncertainties and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information. Any forward-looking information speaks only as of the date on which it is made and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events or results or otherwise. Although Cardiol believes that the expectations reflected in the forward-looking information are reasonable, they do involve certain assumptions, risks, and uncertainties and are not (and should not be considered to be) guarantees of future performance. It is important that each person reviewing this news release understands the significant risks attendant to the operations of Cardiol.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/64626

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Psychedelics: Investing in the Perfect BrainStorm https://mjshareholders.com/psychedelics-investing-in-the-perfect-brainstorm/ Fri, 03 Apr 2020 10:03:05 +0000 https://www.cannabisfn.com/?p=2768574

Ryan Allway

April 3rd, 2020

App, Exclusive, News, Top Story


Psychedelics are rapidly becoming both a mainstream treatment option and investment opportunity. With growing interest among researchers, forward-thinking companies are starting to build a presence in the space. 

In this article, we will take a look at the growing body of therapeutic evidence for psychedelics. How decriminalization is gaining ground, and how Ehave Inc. (OTC: EHVVF) along with other public companies are positioning themselves in the psychedelic space.

A Growing Body of Evidence

A growing body of evidence supports the use of psychedelics to treat a variety of different medical conditions. In 2016, Johns Hopkins researchers found that psilocybin produced a substantial and sustained decrease in depression and anxiety in cancer patients. A follow-up study on the same patients five years later found lasting effects from the one-time therapy.

The therapeutic evidence has become so overwhelming that Johns Hopkins established the Center for Psychedelic and Consciousness Research earlier this year to start rigorously investigating the drugs’ therapeutic potential. Researchers believe that it could have a beneficial impact on everything from smoking addiction to Alzheimer’s disease.

In addition to medical benefits, there’s plenty of anecdotal evidence that microdoses of psychedelics could improve mental health, well-being and productivity. Many prominent business leaders in Silicon Valley, including the late Steve Jobs, praised the benefits of microdosing psychedelics for creativity and cognition.

Click here to receive Ehave News and Investor Updates

Decriminalization Gain Ground

The growing interest among researchers has bolstered attempts by activists to decriminalize psychedelics throughout the country. Denver, Oakland and Santa Cruz have already decriminalized psychedelics over the past year, while California, Oregon and Iowa could see psychedelic-related measures on the ballot in November.

In the nation’s capital, Rep. Alexandria Ocasio-Cortez, D-NY recently introduced legislation that would allow researchers to more easily study the therapeutic and medicinal benefits of psilocybin and other psychedelics. These developments mirror what happened in the early medical cannabis industry where regulations were slowly relaxed over time.

It’s worth noting that these early efforts seek to decriminalize psychedelics and pave the way for research. Unlike the cannabis industry, there’s less interest in a recreational market and more interest in building a viable alternative therapy for countless different medical conditions that impact the brain—many without any current options.

Investors Start Taking Notice

Mind Medicine Inc. (NEO: MMED), better known as MindMed, became the first psychedelic pharmaceutical company to go public earlier this year on the NEO exchange. After raising $24.2 million in pre-public funding, the company plans to initially focus on addressing the opioid crisis and other forms of addiction with the use of psychedelics.

Click here to receive Ehave News and Investor Updates

Ehave Inc. (OTC: EHVVF) is another publicly-traded company in the space. Its Mycotopia Therapy subsidiary recently acquired PsychedeliTech and plans on hosting an inaugural PsyTech Summit in Tel Aviv, Israel on June 14-15, 2020. The conference will be modeled after the highly-successful CannaTech conference and connect key industry participants.

The company believes that it’s Dash platform will play a crucial role in the global advancement of psychedelic research. As a HIPAA and GDPR compliant platform, Dash is secure and compliant with some of the world’s strictest privacy laws. It’s an optimal way to compile psychedelic research and results to provide easy access for scientists globally.

Looking Ahead

Psychedelics are quickly picking up steam among both researchers and investors. As the market opens up, forward-thinking companies are building an early presence in the space before it grows into a large and mainstream industry. Cannabis investors may want to consider building a position in some of these companies given the similarities.

Please click here for additional Information on EHave, Inc. (OTC: EHVVF)

Please click here for additional Information on Mycotopia Therapy

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
More Companies Lining Up to Get Their Hands on Lexaria’s DehydraTECH™ Platform https://mjshareholders.com/more-companies-lining-up-to-get-their-hands-on-lexarias-dehydratech-platform/ Wed, 14 Aug 2019 18:42:06 +0000 https://www.cannabisfn.com/?p=2650152

Ash Stringer

August 14th, 2019

App, Exclusive, News, Top Story




When you’ve got something great, it may take a little bit of time for people to learn about it, but once word starts getting around, it can yield a windfall of interest. That’s the case with Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and its DehydraTECH™ technology that enhances qualities and uptake of all sorts of lipophilic (fat-based) molecules. As such, companies from diverse businesses have partnered with Lexaria recently, including Hill Street Beverage last week.

So What’s the Big Deal with DehydraTECH?

The human body has a natural digestive process that is quite proficient at filtering molecules to ensure safe delivery of only beneficial substances. In scientific nomenclature, a molecule (an oral medicine for example) actually reaching the human bloodstream is referred to as “bioavailability” and it can be a real challenge to do so.

Click on the Video for Education on Lexaria’s DehydraTECH™ technology.

DehydraTECH™ is an efficient Trojan horse for getting molecules delivered in oral form around the filtering process of liver metabolism and into the bloodstream. Lexaria accomplishes this by joining the payload – albeit a vitamin, active pharmaceutical ingredient, nicotine, cannabinoid, etc. – with a microscopic particle of a special type of fat known as LCFA’s (long chain fatty acids). Upon ingestion, the body detects the LCFA, not the molecule hidden alongside. There are a multitude of positive results from this technology, which have been verified through lab and human studies.

Click Here to View Lexaria’s Investor Presentation

For starters, many beneficial molecules taste and smell horrible. DehydraTECH™ eliminates that problem, making them palatable without using sugar like most competitors do today. Even more importantly, the bioavailability profile changes dramatically. The time it takes to feel the effect can be shaved to as little as 10 minutes (as little as 2 minutes in animal testing) from the natural metabolic process that typically takes around 90 minutes. Furthermore, bioavailability can surge as much as 10-fold, meaning the consumer is getting more of what they want and need faster.

Opportunities Abound

The beauty of the DehydraTECH™ technology is that it is easily and cost-effectively implemented into existing manufacturing operations. It appeals to a diverse group of customers because of the many different types of molecules for endless applications. As detailed in the company’s presentation, from pills to coffee, DehydraTECH™ is a highly versatile drug delivery method.

Some of the initial targets being focused on are cannabinoids, NSAIDs such as ibuprofen (non-steroidal anti-inflammatory drugs), vitamins and nicotine. The opportunity to genuinely disrupt the nearly $1 trillion market with the world’s first ingestible nicotine product did not escape Marlboro owner Altria (NYSE: MO). In January, the international tobacco behemoth agreed to put up $12 million for R&D and product development for oral, reduced risk nicotine consumer products using DehydraTECH™ and agreed to pay Lexaria a royalty on products sold with DehydraTECH™ technology.

July Big Month for New Partners

The cannabis market is booming, as more health conscious consumers look to the plant for all of its therapeutic effects. In particular, people are looking to cannabidiol (CBD), a prominent cannabinoid found in hemp and cannabis trumpeted for its benefits for treating everything from dry skin to epileptic seizures.

The legalization of hemp at the start of the year thanks to the passage of the U.S. Farm Bill has the hemp market abuzz and Lexaria is in the thick of it. Early in July, the company’s subsidiary Lexaria Hemp Corp. entered a 5-year agreement to provide DehydraTECH™ technology to Nic’s Beverages Ltd for use in CBD-based beverages to be produced and sold throughout America.

Nic’s is the fourth company (3 in the U.S. and 1 in Canada) to license the technology for beverages. Nic’s plan is to begin making ready-to-drink cold brew coffees enhanced with CBD from multi-spectrum hemp oil.

“DehydraTECH™ technology is perfect in allowing us to deliver CBD from hemp oil with zero impact on our cold brewed coffee’s outstanding aroma or flavor,” commented Nic’s CEO John Goodpasture.

A day after the Nic’s deal was disclosed, Lexaria said it inked a 5-year deal to provide DehydraTECH™ to B2B manufacturing company Universal Hemp LLC. Universal Hemp will be using the technology for its hemp-derived CBD bulk ingredients it supplies to the nutraceutical and consumer packaged goods industries throughout the U.S. and Canada.

“In terms of bioavailability, shelf stability and taste, [DehydraTECH™] is the best performing technology in the market, hands down,” said Chad Kahunahana, CEO and Founder of Universal Hemp about the partnership.

Future royalties and other financial terms were kept confidential, but it was revealed that the deal has minimum down payments over the life of the contract of US$3.75 million.

Lexaria kept the momentum going all month, announcing a 10-year joint manufacturing partnership (JMP) with Hill Street Beverage Co. (TSX-V: BEER) to create commercial products utilizing DehydraTECH. Per the pact, the companies will work together to make THC cannabis and/or CBD hemp powder for all new (and yet unnamed) consumer products in the form of tablets, capsules and packets.

Click Here to View Lexaria’s Investor Presentation

The JMP will also produce similar powders as a bulk ingredient for manufacturing processes for sale to other licensed producers seeking to use Lexaria’s advanced infusion technologies to create their own wide variety of products for sale within Canada.

Hill Street is in the midst of completing the acquisition of OneLeaf Cannabis. Manufacturing of the new goods, which will be handled by Hill Street and utilize DehydraTECH™ in the process, is expected to be done at OneLeaf’s cultivation and processing facility in Regina, Saskatchewan, pending all Health Canada approvals.

For its part in bringing DehydraTECH™ to the table, Lexaria is entitled to 50% of the new company’s profits.

The companies are making the moves now to be properly positioned when cannabis-infused edibles become legal throughout Canada later this year.

The JMP may be new, but the relationship between Hill Street and Lexaria is not. Hill Street had previously licensed the DehydraTECH™ technology for CBD-infused beverage sales in Canada. Last week, a new 10-year agreement was forged giving Hill Street global rights on a semi-exclusive basis.

It seems that CEO’s of consumer product companies are enamored with DehydraTECH: “Lexaria has proven themselves time and again to be the ideal infusion platform for our products,” commented Hill Street’s Chairman and CEO, Terry Donnelly.

Under the terms of the agreement, Hill Street is paying Lexaria US$1.8 million in BEER stock, most up front, with the remainder owed upon meeting milestones for entering new international markets.

Lexaria announced in August that they’ve received a cannabis R&D license from Health Canada that does not expire until August 2023, allowing the company for the first time ever to place its state-of-the-art laboratory into operation and accelerate a truly impressive research program.

“Lexaria has evolved so rapidly and achieved so much in the past eight months, that we are nearly unrecognizable compared to the end of 2018,” said Chris Bunka, Chief Executive Officer of Lexaria. “We’re signing new customers at ten times the rate of previous years; we’ve partnered with one of the largest companies in North America; additionally, we’ve just completed construction of one of the most advanced labs in the industry. 2019 has been a fabulous year so far and we think it will only get better, and drive strong new revenues and advances into 2020 and far beyond.”

The most recent sign of those advances is the appointment of Mr. Brian Quigley to their board of directors. Mr. Quigley most recently spent 16 years at Altria Group, 7 of those years were spent as President and Chief Executive Officer for U.S. Smokeless Tobacco and Nu-Mark, Altria’s innovation company. It was during that period of time that the existing business relationship between Altria and Lexaria was negotiated.

“I am thrilled to be joining the already strong team at Lexaria Bioscience. From my first engagement with Chris, it was clear to me that Lexaria and its leadership team is positioned to create change through innovation in both the Cannabis and Nicotine space. It is an honor to join this team after forging such a strong partnership with them during my time with Altria.”

Consumer Products Company? Licensing Company? Try Both.

Because Lexaria has two brands of its own: ViPova (a beverage lineup of teas and coffee) and both TurboCBD capsules and ChrgD+ powdered drink mix, they sometimes get lumped in with other CBD consumer brands companies. Adding in the new venture with Hill Street adds to that assumption.

Fact is though, technology licensing is at the core of Lexaria’s business. Candidly, it is a far more lucrative business too, with margins generally 90+%. With a robust patent estate of about a dozen issued patents and more than 60 additional pending, management has built itself a strong position with a better solution than sweeteners and chemicals for any and all ingestible products by merely adding one step to the manufacturing process.

When more companies continue to learn that they can add DeyhydraTECH™ to their operations to make lipophilic compounds palatable with superior bioavailability for only a fraction of a penny per product serving, there is likely going to be more companies knocking on Lexaria’s door.

Click Here to View Lexaria’s Investor Presentation

Click Here For More Information on Lexaria Bioscience Corp.

Click Here to Receive CFN Media’s Newsletter Every Week in Your Inbox

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

Avatar

About Ash Stringer


]]>
Pascal Biosciences Announces Formation of Clinical Advisory Board https://mjshareholders.com/pascal-biosciences-announces-formation-of-clinical-advisory-board/ Wed, 08 May 2019 17:00:44 +0000 https://www.cannabisfn.com/?p=2456119 VANCOUVER, British Columbia and SEATTLE, May 08, 2019 (GLOBE NEWSWIRE) — Pascal Biosciences Inc. (TSX.V:PAS)(“Pascal” or the “Company”), a drug discovery and development company, today announced it has formed a clinical advisory board (“CAB”) of preeminent neuro-oncology experts to guide its PAS-403 therapeutic program. PAS-403 is Pascal’s clinical candidate for the treatment of glioblastoma, a devastating brain cancer with limited therapeutic options.

“We are extremely fortunate to have assembled this world-renowned group of leading researchers and clinicians in the field of neuro-oncology,” said Dr. Patrick Gray, CEO of Pascal. “Their knowledge and insights will guide our PAS-403 program for the treatment of glioblastoma. Only three treatments have been approved in the last 30 years for glioblastoma. After reviewing our data, our CAB has strongly encouraged us to proceed with PAS-403 clinical trials to make advancements for this devastating disease.”

Members of the clinical advisory board include:

  • Chair: Dr. Darell Bigner – E.L. and Lucille F. Jones Cancer Research Professor, Duke University School of Medicine

    Dr. Bigner is founding Director of the Preston Robert Tisch Brain Tumor Center. His research has involved the investigation of the causes, mechanism of transformation, altered growth control, and development of new methods of therapy for primary brain tumors and those metastasizing to the brain. Dr. Bigner has over 600 scientific publications and received the Lifetime Achievement Award from the Society of Neuro-Oncology in 2014.

  • Dr. Mitchell Berger – Professor and Chair, Neurological Surgery, University of California, San Francisco

    Dr. Berger is an internationally recognized expert in treating brain and spinal cord tumors in adults and children. He is co-director of the Adult Brain Tumor Surgery Program, director of the Brain Tumor Research Center and director of the Center for Neurological Injury and Repair. Dr. Berger is a past-president of the Society for Neuro-Oncology (1997-1999), has received the Victor Levin Award in Neuro-oncology Research from the Society of Neuro-Oncology in 2015, was named on the Blue Ribbon Panel of scientific experts for the National Cancer Moonshot Initiative, and has also served as president of the American Association of Neurological Surgeons.

  • Dr. Timothy Cloughesy – Professor of Neurology, University of California, Los Angeles

    Dr. Cloughesy is Director of the UCLA Neuro-Oncology program. Dr. Cloughesy’s research focuses on clinical trials in brain cancer using targeted molecular therapies with novel clinical trial design. He has developed a brain cancer bioinformatics database which combines clinical outcomes, imaging and molecular analysis to enhance translational research. For more than a decade, he has been recognized as both a Top Doctor and Top Doctor for Cancer by U.S. News.

  • Dr. Patrick Wen – Professor of Neurology, Harvard Medical School

    Dr. Wen is Director of the Center for Neuro-Oncology, Dana Farber Cancer Research Institute and Director of the Division of Cancer Neurology at Brigham and Women’s Hospital. Dr. Wen’s research is focused on novel treatments of brain tumors, especially targeted molecular agents, and optimizing response assessment and clinical trial endpoints in neuro-oncology. He currently serves as President of the Society of Neuro-Oncology, the premier North American organization for health care professionals focusing on central nervous system tumors in children and adults.

  • Dr. Andrew Sloan – Professor, Departments of Neurological Surgery and of Pathology, School of Medicine, Case Western Reserve University

    Dr. Sloan serves as Director of the Brain Tumor and Neuro-Oncology Center at the Seidman Cancer Center and is also Vice Chairman of Neurosurgery at University Hospitals Cleveland Medical Center. His clinical and research interests focus on the biology and treatment of tumors of the brain and spine. He has been recognized by his peers as one of the “Best Doctors in America” since 2003, and as one of the “Top Surgeons in America” since 2007. In 2014, he was elected President of the Ohio State Neurosurgical Society.

Pascal has demonstrated that PAS-403 is active against human glioblastoma cells in cell culture, accumulates in the brain, has a good safety profile, and displays striking synergy with standard of care in an animal model of glioblastoma. With input from our CAB, a clinical plan is being developed for testing PAS-403 in glioblastoma patients.

About Pascal Biosciences Inc.

Pascal is a biotechnology company focused on advancing innovative approaches for the treatment of cancer including cannabinoid-based therapeutics and targeted therapies. The Company’s leading portfolio comprises a small molecule therapeutic, PAS-403, that is advancing into clinical trials for the treatment of glioblastoma, and PAS-393, an immuno-stimulatory cannabinoid to be used in combination with checkpoint inhibitor therapy. In addition, Pascal is developing a B-cell targeted antibody for acute lymphoblastic leukemia. For more information, visit www.pascalbiosciences.com.

Investors:
[email protected]

Media Contact:
Julie Rathbun

[email protected]
Tel: 206-769-9219

DISCLAIMER
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release”.

Primary Logo

]]>
Interview with Gabriella’s Kitchen CEO Margot Micallef https://mjshareholders.com/interview-with-gabriellas-kitchen-ceo-margot-micallef/ Tue, 19 Mar 2019 18:44:41 +0000 https://www.cannabisfn.com/?p=2328854

Ryan Allway

March 19th, 2019

Uncategorized


CFN Media recently sat down with Gabriella’s Kitchen (CSE: GABY) (OTCBB:GABLF) CEO Margot Micallef to discuss the global implications of Gaby’s innovative products.

New beginnings

Gabriella’s Kitchen is a cannabis wellness company founded in health and nutrition. Spurred by a dire cancer prognosis, sisters Gabriella and Margot sought a healthier lifestyle that might prolong Gabriella’s life.

Thus, Gabriella’s Kitchen was formed. Proving that consumer demand was real, the business took off. Gaby went from 200 retail outlets to 3,400, and growing to 2018 revenue of over $9 million dollars.

Leading the Field

As CEO, Micallef’s visionary role was driven by her sister’s condition as she searched wellness and nutrition science relentlessly. Though she had never previously explored cannabis products, her quest led her to the many case studies and current research based on the health attributes associated with the cannabis plant.

Convinced that the properties of cannabis could enhance her products, Micallef sought out the pioneers in the field and found Mara Gordon, process engineer and CEO of The Oil Plant (TOP), and Jamie Fay, a seasoned executive in packaged goods.

Gordon had her own health problems and her search for wellness paralleled Micallef’s. The two joined forces, merged companies, and have now released many new products, infused with cannabis and healthy ingredients, to promote the field of well being through nutrition.

The documentary “Weed the People” features Gordon’s groundbreaking and data-oriented work. Working with clinicians and physicians, Gordon explores five families that have successfully used cannabis to treat a variety of cancers. Gordon’s previous advisory status at GABY was so successful that she was assigned Chief Research Officer. With Gordon’s proprietary knowledge and TOP’s cost effective, high grade, whole plant oil extraction, all the right ingredients came together for GABY’s kitchen.

Meanwhile, Fay has senior-level executive experience from Hain Celestial, Nature’s Path Foods and Mars Inc. and brings extensive packaged goods expertise to the table. He joins his former colleagues, Maureen Putman and Irwin Simon, in applying natural and organic food industry successes to the nascent cannabis industry.

Looking Ahead

Gifted with gratitude and acknowledgement of Gordon’s work, Micallef seeks to make cannabis available to all who are suffering with illness through legalization. Micallef recognizes California, currently the greatest producer of cannabis and also the largest market of wellness products, to be a forerunner in consumer habits. Micallef is banking on the “halo” effect as legalization spreads and markets go global.

The TOP acquisition provided the company with a Type-6 non-volatile manufacturing license to operate a cannabis extraction and infusion facility in the state of California. GABY is also in the process of acquiring Sonoma Pacific Distribution, a leading California cannabis distribution and marketing company. The addition of Sonoma’s licensed distribution channel gives the company control of the product life cycle from conception through manufacturing to wholesale in the world’s largest legal cannabis market. GABY is also aiming for markets in Canada, where federal legalization has recently occurred and where edibles are expected to be legalized later this year.

The company also recently joint ventured with Eximius Coffee to introduce cannabis and CBD-infused ready-to-drink cold brew coffee and pods. The coffees for the licensed dispensary channel will be manufactured at TOP while those aimed for the mainstream grocery and convenience channel using hemp CBD oil will be manufactured through a partnership relationship with an Oregon facility. In addition to near-term revenue potential, the deal could pave the way to wider entry into the beverage market.

GABY’s ability to adapt and expand is well ensured, as exports out of Canada are free to fly to global markets far and wide. With this distribution infrastructure in place, Gabriella’s Kitchen continues to be a thought leader and intends to leave a global footprint for their innovative products. As such, the company offers the opportunity for investors to participate in an early stage cannabis play that looks well-positioned to take off.

For more information, Gabriella’s Kitchen can be found at: www.gabriellas-kitchen.com

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Aleafia Health Study Indicates 45% of Patients End Benzodiazepine Use Following Medical Cannabis Treatment https://mjshareholders.com/aleafia-health-study-indicates-45-of-patients-end-benzodiazepine-use-following-medical-cannabis-treatment/ Fri, 25 Jan 2019 15:49:50 +0000 https://www.cannabisfn.com/?p=2205272

Ryan Allway

January 25th, 2019

News, Top News


Authors Leveraged Aleafia’s 10 Million Point Medical Cannabis Dataset

TORONTO, Jan. 25, 2019 (GLOBE NEWSWIRE) — Aleafia Health Inc. (TSXV: ALEF, OTC: ALEAF, FRA: ARAH) (“Aleafia Health” or the “Company”), announces today what it believes to be the first study reporting reduced benzodiazepine use among patients initiated and monitored on medical cannabis. Benzodiazepines, a class of psychoactive drugs, include the most common sedatives and anti-anxiety medications.

The retrospective study, published in Cannabis and Cannabinoid Research, a peer-reviewed journal, is entitled “Reduction of Benzodiazepine Use in Patients Prescribed Medical Cannabis.” It found that 45.2 per cent of patients regularly consuming benzodiazepines had stopped taking the medication within approximately six months of beginning medical cannabis. These patients, following prescription cannabis use, also reported decreased daily distress due to medical conditions.

The cohort featured 146 patients who received physician-led treatment in Aleafia Health’s wholly owned Canabo Medical Clinics (“Canabo”). Aleafia believes it maintains the world’s largest medical cannabis patient dataset and is deploying the data for unique insights in medical cannabis treatment and product development best practices.

The Canadian Centre on Substance Abuse and Addiction (CCSAA) warns that benzodiazepines may lead to serious long-term complications, including dependence, overdose and death. According to a CCSAA study, 10 per cent of the Canadian population takes prescription sedatives. And a study published in The British Medical Journal found that benzodiazepines consumption significantly increased the risk of opioid overdose.

“The study results are encouraging, and this work is concurrent with growing public interest in a rapidly developing Canadian cannabis market,” said lead author Chad Purcell. “We are advising the public to observe caution. The results do not suggest that cannabis should be used an alternative to conventional therapies. Our purpose is inspiring others to advance current cannabis understanding as we collect stronger efficacy and safety data that will lead to responsible policy and recommended practices for use.”

“Due to regulatory hurdles and lingering stigma, there remains a shortage of medical cannabis research. At Aleafia, we will continue to leverage our IP and leading cannabis data to further advance patient care through advanced treatment methods and specialized product development,” said Aleafia Health Chief Medical Officer Dr. Michael Verbora. “This study’s results will not be surprising to many patients who have transitioned from prescription pain killers and sedatives with the help of physician-led medical cannabis therapy. I thank the study authors for this significant contribution to evidence-based medicine.”

Learn more at www.AleafiaInc.com/Invest.

For Investor & Media Relations, please contact:

Nicholas Bergamini, VP, Public Affairs
416-860-5665
[email protected]

About the Authors:

Chad Purcell BSc (Pharm)

Chad Purcell will receive an MD degree from Dalhousie University in 2019 from which he also earned a BSc with honours in pharmacology and, subsequently, a BSc in pharmacy. He has published in several areas of pharmaceutical research including pharmacokinetics, pharmacy practice and most recently, medical cannabis

Dr. Andrew Davis

Dr. Andrew Davis received a Ph.D. and M.A. in Economics from the University of Rochester, where he also held both a Sproull and Lionel McKenzie Fellowships. He also earned a B.Sc. from Memorial University of Newfoundland. Dr. Davis has regularly presented research at a variety of seminars and conferences including the Canadian Economics Association, of which he is a member, and is most recently published in Economic Modelling.

Dr. Nico Moolman, MD

Dr. Nico Moolman is a Clinical Assistant Professor at the University of Saskatchewan in Saskatoon. He specializes in Otolaryngology – Head and Neck surgery with a focus on Sinonasal, as well as Facial Plastic and Reconstructive surgery. His research has focused on Head and Neck Oncology with publications in the field.

Dr. Mark Taylor, MD

Dr. Mark Taylor, currently a Professor as well as the Interim Head of the Division of Otolaryngology-Head and Neck Surgery at Dalhousie University, has 15 years’ experience as a Head and Neck Surgeon in Halifax. In addition to resident education, his practice focuses on Head and Neck Oncology, as well as Facial Plastic and Reconstructive Surgery, in which he is also Board Certified. Dr. Taylor has over 150 peer- reviewed publications to his credit and has developed a particular interest in research into cannabinoid therapy.

About Aleafia Health:

Aleafia, a vertically integrated, national cannabis company, operates major medical clinic, cannabis cultivation and R&D facilities. A federally licensed producer and vendor of cannabis, the company has a planned and fully-funded annual production capacity of 98,000 kg of dried cannabis flower.

Aleafia operates medical cannabis clinics staffed by physicians and nurse practitioners, with over 50,000 patients. The company is highly differentiated, maintaining the largest medical cannabis dataset in the world.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

FORWARD LOOKING INFORMATION

This press release contains forward-looking statements and information that are based on the beliefs of management and reflect the Company’s current expectations. When used in this press release, the words “estimate”, “project”, “belief”, “anticipate”, “intend”, “expect”, “plan”, “predict”, “may” or “should” and the negative of these words or such variations thereon or comparable terminology are intended to identify forward-looking statements and information. The forward-looking statements and information in this press release includes information relating to the implementation of Aleafia Health’s business plan. Such statements and information reflect the current view of the Company with respect to risks and uncertainties that may cause actual results to differ materially from those contemplated in those forward-looking statements and information.

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following risks: risks associated with the implementation of Aleafia Health’s business plan and matters relating thereto, risks associated with the cannabis industry, competition, regulatory change, the need for additional financing, reliance on key personnel, the potential for conflicts of interest among certain officers or directors, and the volatility of the Company’s common share price and volume. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made, and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Investors are cautioned against attributing undue certainty to forward-looking statements.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/ab9e9601-882f-4da8-84f4-7f0bfc1062c0

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Pascal Biosciences Provides Year-End Investor Update and Reviews Upcoming Milestones https://mjshareholders.com/pascal-biosciences-provides-year-end-investor-update-and-reviews-upcoming-milestones/ Thu, 20 Dec 2018 20:39:55 +0000 http://www.cannabisfn.com/?p=2117445

Ryan Allway

December 20th, 2018


 2018 pipeline expansion includes lead cannabinoid-based cancer therapeutic
– Clinical trial in glioblastoma to begin in 2019

VANCOUVER, British Columbia and SEATTLE, Dec. 20, 2018 (GLOBE NEWSWIRE) — Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced a year-end review of accomplishments during 2018 and insight into plans for 2019.

“Pascal today is a much different company from that of just a year ago. We have two promising cannabinoid therapeutic programs close to clinical evaluation, secured a Schedule I research license for cannabinoid research and have strengthened our leadership team to support our development efforts,” said Dr. Patrick Gray, CEO of Pascal. “We look forward to beginning clinical evaluation of our product ST-403 in glioblastoma and further advancing our promising cannabinoid research efforts in the coming year.”

2018 Highlights

Research:

  • Announced discovery that cannabis contains compounds capable of stimulating the immune system to destroy tumor cells. While cannabinoids have long been known to be helpful in treating cancer symptoms like nausea and pain, Pascal was the first to identify a mechanism in which cannabinoids may provide a direct benefit in immunotherapy. We believe certain cannabinoids may activate the immune system to destroy cancer cells and hopefully improve the efficacy of checkpoint inhibitors, the most exciting class of new therapeutics. Pascal is planning to test select compounds in volunteers and patients.
  • Received a US Drug Enforcement Administration (DEA) Schedule I Research license to enable cannabinoid research work. Very few research organizations obtain a Schedule I license and most are universities. Obtaining the license is a very rigorous process and enables Pascal to conduct research on cannabinoids, to develop a cannabinoid product, and to conduct clinical trials on cancer patients.
  • In October Pascal licensed a cannabinoid-based product for the treatment of glioblastoma and brain metastases. Glioblastoma is a devastating disease that strikes 15,000 patients each year in North America, and the median survival rate is only 12 to 17 months. Our compound is very effective in a mouse model of glioblastoma, and Pascal plans to begin human clinical studies in 2019.  This program is the culmination of 20 years of effort by renowned cannabis researcher Dr. Nephi Stella, founder and co-director of the University of Washington Center for Cannabis Research. Dr. Stella is now a consultant for Pascal, and he has been very helpful with both of Pascal’s cannabinoid programs.

Additions to Board and Management Team:

  • Julie Eastland was appointed to the Pascal Board of Directors this summer. Julie is an accomplished financial executive, with more than 25 years of experience in public and private biotechnology companies. Most recently she was Chief Business Officer and Chief Financial Officer of Cascadian Therapeutics, where she negotiated and managed their acquisition by Seattle Genetics, in a deal valued at $810M. Julie has the financial and corporate development experience that Pascal needs going forward.
  • Pascal strengthened its leadership team with the appointments of accomplished executives in therapeutic and business development. This includes Kevin Egan, Vice President of Business Development. He has been in biotech for over 30 years and has a proven track record of negotiating partnering, licensing, and outsourcing deals.  Dr. Tom Deckwerth, Vice President of Therapeutic Development, has 20 years of industrial experience in therapeutic development.  And Dr. Larry Tjoelker, Vice President of Research, has over 25 years of research experience in the biotechnology industry.

“The extensive experience of Julie, Kevin, Tom, and Larry will be invaluable as we advance our leading cannabinoid-based programs and explore strategic opportunities,” said Gray.

Looking ahead to 2019

Pascal is targeting to initiate clinical trials of ST-403 in glioblastoma next year. Manufacturing efforts have already begun, and formulation, safety studies, and clinical studies are all being planned with a strict timeline.

Second, Pascal has put much effort into its immune-stimulatory cannabinoid program in collaboration with our founder Dr. Wilf Jefferies at the University of British Columbia. This work will be published in peer-reviewed scientific articles, and you will hear a lot more about this program going forward, including plans for studies in human volunteers and patients.

“The world of drug development is exciting and promising, but it is also costly and time consuming. Along with the risk, there is great value in a successful product that provides benefit to patients,” said Gray. “While we are at an early stage in this process, we have the faith and enthusiasm that we will be successful. And we are driven by the knowledge that patients need a cure.  Patients and their families contact us to ask when they can be tested—this is the reason we come to work each day, and this is the reason we are driven to make our products available as quickly as possible.”

About Pascal Biosciences Inc.

Pascal Biosciences is a biotechnology company focused on advancing innovative approaches for the treatment of cancer including cannabinoid-based therapeutics and targeted therapies. The company’s leading cannabinoid portfolio comprises a small molecule therapeutic, ST-403, that is advancing into clinical trials for the treatment of glioblastoma, and an immuno-stimulatory molecule. In addition, Pascal Biosciences is developing a B-cell targeted antibody for acute lymphoblastic leukemia and an antibody for calcium channels expressed by the immune system. For more information, visit www.pascalbiosciences.com.

Investors:
[email protected]
Tel: 206-221-3443

Media Contact:
Julie Rathbun
Tel: 206-769-9219

DISCLAIMER
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release”

pascallogo.jpg

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Creso Pharma Brings Together Cannabis Experts Across Several Verticals https://mjshareholders.com/creso-pharma-brings-together-cannabis-experts-across-several-verticals/ Tue, 18 Dec 2018 19:37:29 +0000 http://www.cannabisfn.com/?p=2105050

Ryan Allway

December 18th, 2018

Exclusive, Top News


The due diligence process looks very different for small-cap versus large-cap stocks. When analyzing large-cap companies, investors pay closest attention to financial statements and valuation ratios to extrapolate growth rates and apply multiples. Small-cap stocks tend to be earlier stage companies without an established earnings track record, which means that investors must consider the management team above all else.

Creso Pharma Ltd. (ASX: CPH) is a small-cap company founded in 2016 that has amassed one of the most experienced management teams in the cannabis industry. By bringing together experts across pharmaceutical, cannabis, and investment banking industries, the company is well positioned to execute on its unique approach to the market and become a leading provider of cannabis to people and animals worldwide.

In this article, we will take a closer look at the company’s management team and advisory board, as well as how their expertise have helped drive progress.

Click here to receive the investor presentation and going public alert

Experienced Management Team

Many investors in small-cap companies look for experience in both operational areas and investment banking when conducting due diligence. After all, public companies must both execute their business plan and deal with the ins and outs of being publicly traded.

Creso Pharma was founded by three individuals with extensive experience spanning the global pharmaceutical, medical cannabis, and investment banking industries:

  • Creso Pharma CEO, Co-Founder, and Executive Director Dr. Miri Halperin Wernli, PhD, MBA, has over 25 years of strategic and operational leadership in global drug and product development in the pharmaceutical and biomedical industries.
  • Non-Executive Chairman and Co-Founder Boaz Wachtel is a leading medical cannabis expert that formerly managed Phytotech Medical (ASX: MMJ)—Australia’s first publicly-traded medical cannabis company.
  • Non-Executive Director and Co-Founder Adam Blumenthal has over ten years of experience in investment banking and corporate finance. He has deep experience in both Australian and international markets, having helped raise capital and finance several listed and unlisted companies, including several medical cannabis firms.

These co-founders are joined by Chief Operating Officer John Griese—an expert in cannabis and food manufacturing and supply chain management. Over the past 30 years, he has worked with companies like Pepsi and Nestle in executive roles. More recently, he developed cannabis experience as Chief Operating Officer of Bloom Farms—a large branded manufacturer and distributor in California’s regulated market.

Click here to receive the investor presentation and going public alert

Strong Advisory Board

Advisory boards are equally important to investors, especially in tightly-regulated industries. Board members can provide tremendous insights into everything from navigating regulatory red-tape to developing innovative new products.

Creso Pharma has developed a strong advisory board across these areas:

  • Dr. Isaac Kobrin, MD, is an internist with more than 15 years of experience in the United States and Israel. He also has over 22 years of experience in the pharmaceutical industry in Roche and Actelion, where he was responsible for the development of key compounds.
  • Dr. Stephane Redey, PhD, has over 18 years of experience leading teams in the technical development of innovative drugs and strategic outsourcing. He has held senior positions with pharmaceutical companies in Switzerland and Australia.
  • Dr. Raquel Peyraube, MD, has over 28 years of experience in training, prevention, treatment, and harm reduction, while also consulting on drug policy reform in Latin America.
  • Prof. Dr. Felix Gutzwiller, MD, MPH, PhD, has served as a professor at the University of Basel and a professor of Social and Preventive Medicine at the University of Zurich, Emeritus since 2013.
  • Dr. Gian Trepp ETH, MBA, IMD, is a senior pharmaceutical marketing executive with over 18 years of strategic and operational leadership. In addition to holding senior roles at global companies, he founded GBT Pharma, UK.
  • Jorge Wernli ETH, MBA, IMD, is an expert in market access, pricing reimbursements, and government affairs with more than 30 years of experience working with startups and large pharmaceutical companies. He has built relationships across Europe, South America, and several Asian countries.
  • Prof. Dr. Walter P. von Wartburg is an attorney at law with international experience in the areas of health and communication PR. For over 20 years, he has provided legal, communication, and issues management advice to biotech and life science firms.

Looking Ahead

Creso Pharma Ltd. (ASX: CPH) has made tremendous progress in its mission to bring pharmaceutical rigor to the cannabis industry under this leadership. Over the past two years, the company acquired several cannabis assets, listed on the ASX (and soon TSX-V), and began generating early revenue through cultivation and product development. Investors may want to keep an eye on the stock given management’s proven execution.

For more information, visit the company’s website or Click here to receive the investor presentation and going public alert

Disclaimer 

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Canntab Partners with Leading Surgeon to Conduct Pain Management Trial https://mjshareholders.com/canntab-partners-with-leading-surgeon-to-conduct-pain-management-trial/ Fri, 14 Dec 2018 14:15:09 +0000 http://www.cannabisfn.com/?p=2071287

Ryan Allway

December 14th, 2018

Exclusive, Top News


The opioid industry is expected to generate nearly $20 billion in annual revenue by 2020, but the addictive nature of the drug has doctors and patients increasingly concerned. With the legalization of cannabis across Canada and many U.S. states, there’s an opportunity to replace dangerous opioids with efficacious cannabinoids to treat chronic and acute pain. Investors may want to take a closer look at companies focused in these areas.

Canntab Therapeutics Ltd. (CSE: PILL) (FSE: TBF1) recently announced a partnership with world-renowned orthopaedic surgeon, Dr. Don Garbuz, MD, to conduct a clinical trial to analyze the efficacy of cannabis as a replacement for opioids in postoperative care. The study is expected to cost about $600,000 and take between 12 and 18 months to complete. If successful, it could open the door to significant pain management markets.

Surgical Pain Management

Most patients undergoing surgery are prescribed opioids to control their postoperative pain, such as OxyContin®, Percocet®, or Vicodin®.

Opioids travel through the bloodstream to the nervous system where they attach to specialized proteins, called OP1, OP2, or OP3 receptors, on the surfaces of opiate-sensitive neurons. Through a series of cellular events and mechanisms, the linkage of opioids to these receptors produces an analgesic effect and triggers the same biochemical processes that reward people with feelings of pleasure.

The effectiveness and widespread use of opioids has created a market that could reach $18.4 billion by 2020, making it one of the most successful classes of pharmaceutical drugs.

The problem is that opioids can be very addictive. The body builds up tolerance to opioids over time, which means that greater and greater doses are required to achieve the same effects. In addition, chronic opioid use creates brain abnormalities that create withdrawal symptoms when a person tries to stop taking opioids. More than 115 people die every day from opioid overdoses in the U.S. alone, while costs have reached $78.5 billion per year, including the costs of healthcare, lost productivity, addiction treatment, and criminal justice involvement

The legalization of cannabis across Canada and in many U.S. states has created a unique opportunity to combat the crisis by prescribing cannabis as an alternative. Unlike opioids, cannabinoids act on the body’s endocannabinoid system to generate an analgesic effect—users don’t even need to experience the high of THC. Cannabis is also far less addictive and nobody has overdosed on cannabis and died—the same cannot be said for opioids where overdose deaths are commonplace.

Canntab’s Promising Trial

Canntab Therapeutics recently launched a research partnership with Dr. Don Garbuz, MD, Head of the Division of Lower Limb Reconstruction and Oncology of the Department of Orthopaedics at the University of British Columbia. Under the terms of the agreement, the two parties aim to conduct a study to examine and quantify the efficacy of Canntab products in replacing opioids in preoperative and postoperative pain management.

Subject to approval from the University of British Columbia, the partnership will begin clinical trials at the university using Canntab tablets to treat pain after knee-replacement surgery under the direction of Dr. Garbuz. The tablets will be manufactured at FSD Pharma’s (CSE: HUGE) Coburg, Ontario facility under its partnership that was established in September, while initial upfront fees will be covered by Canntab.

Canntab’s solid oral dose delivery systems include extended release (XR), flash melt, immediate release, modified release, and bi-layered tablets that provide a variety of cannabinoid and terpenoid blends in exacting dosages. Protected by 13 patents pending in the United States and Canada, the technology could revolutionize the cannabis industry by providing more pharmaceutical-like options that have exact dosing and familiar protocols.

Looking Ahead

Canntab Therapeutics Ltd. (CSE: PILL) (FSE: TBF1) is well-positioned to offer an alternative to opioids to both combat harmful addictions and capture a meaningful portion of the multi-billion dollar market. With clinical trials underway, the company is drawing closer to commercialization while creating numerous potential catalysts for the stock.

For more information, visit the company’s website at www.canntab.ca.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>